Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.

Jorga, K; Fotteler, B; Banken, L; Snell, P; Steimer, J L

Jorga, K; Fotteler, B; Banken, L; Snell, P; Steimer, J L.

Affiliation

Jorga K; Department of Research and Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland. karin.jorga@roche.com

Br J Clin Pharmacol ; 49(1): 39-48, 2000 Jan.

Article in En | MEDLINE | ID: mdl-10606836

Subject(s)

Antiparkinson Agents/pharmacokinetics; Benzophenones/pharmacokinetics; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors/pharmacokinetics; Parkinson Disease/metabolism; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents/administration & dosage; Antiparkinson Agents/therapeutic use; Area Under Curve; Benserazide/therapeutic use; Benzophenones/administration & dosage; Carbidopa/therapeutic use; Enzyme Inhibitors/administration & dosage; Female; Humans; Levodopa/therapeutic use; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease/drug therapy; Population; Risk Factors; Single-Blind Method; Tolcapone

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Benzophenones / Enzyme Inhibitors / Catechol O-Methyltransferase Inhibitors / Antiparkinson Agents Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2000 Document type: Article

Fulltext

XML

PubMed Links

Search on Google